Phase II study of first line capecitabine administered on continuous way combined with oxaliplatin and bevacizumab every two weeks in metastatic colorectal cancer patients.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2011
At a glance
- Drugs Bevacizumab; Capecitabine; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 23 Aug 2011 Planned end date changed from 1 Jun 2009 to 1 Jan 2011 as reported by ClinicalTrials.gov.
- 02 Oct 2006 New trial record.